STOCK TITAN

HEMOGENYX PHARMACEUTICALS - HOPHF STOCK NEWS

Welcome to our dedicated page for HEMOGENYX PHARMACEUTICALS news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on HEMOGENYX PHARMACEUTICALS stock.

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is a biopharmaceutical group focused on developing new therapies and treatments for blood diseases. The company's Chimeric Bait Receptor platform shows promise in treating cancers like Non-Hodgkin Lymphoma and solid tumors. Hemogenyx Pharmaceuticals utilizes Artificial Intelligence for protein structure simulations and mRNA synthesis to expedite R&D efforts. With recent FDA consents for Phase I trials of HEMO-CAR-T for AML, the company is advancing towards potentially life-saving treatments.

Rhea-AI Summary

Hemogenyx Pharmaceuticals announced total voting rights as of February 28, 2023, confirming the issuance of 1,141,999,321 ordinary shares with a nominal value of 1 pence each. The company holds no treasury shares, resulting in the same number of voting rights available to shareholders. This figure is crucial for shareholders to determine their reporting obligations concerning changes in their shareholdings under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals has successfully raised £4,056,250 through the issuance of 162,250,000 new ordinary shares at 2.5 pence per share. This fundraising effort will support the advancement of their HEMO-CAR-T product candidate into clinical trials and the development of their Chimeric Bait Receptor (CBR) platform. The shares are expected to be admitted for trading on the London Stock Exchange around February 2, 2023, increasing the total issued capital to 1,141,999,321 shares. CEO Dr. Vladislav Sandler highlighted the importance of moving forward with their key products to combat viral infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals plc has successfully completed its third Process Qualification run for the manufacturing of HEMO-CAR-T cells in cGMP compliant facilities. This achievement is crucial for the submission of an Investigational New Drug (IND) application to the FDA, required for initiating Phase I clinical trials. The company will conduct analytical release tests to ensure the quality of these cells, which will also be tested by a third party before the data is compiled for the IND submission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals has completed its second Process Qualification run for the manufacturing of HEMO-CAR-T cells in compliant clean rooms. This step is crucial for filing an Investigational New Drug application with the FDA, necessary for starting Phase I clinical trials. The company plans to execute a minimum of three identical manufacturing runs to meet regulatory requirements. The progress underscores Hemogenyx's commitment to advancing therapies for severe blood diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
77.3%
Tags
none
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals has successfully completed its first Process Qualification (PQ) run for the manufacture of HEMO-CAR-T cells, a crucial step in preparing for the Investigational New Drug (IND) application to the FDA. This PQ run is part of at least three required identical runs to facilitate the IND submission necessary for Phase I clinical trials. The process was executed in a cGMP-compliant environment, followed by quality verification tests on the manufactured cells, indicating readiness for further regulatory steps in the development of new therapies for blood diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Hemogenyx Pharmaceuticals plc has successfully completed its second and final Process Development run for HEMO-CAR-T cell manufacturing in cGMP-compliant facilities. This advancement is a crucial step towards submitting the Investigational New Drug application to the FDA for initiating Phase I clinical trials of HEMO-CAR-T. The company is now preparing for engineering runs as part of its Process Qualification phase. Hemogenyx focuses on developing innovative therapies for serious blood diseases and aims to enhance patient access to life-saving bone marrow transplants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals has released its interim results for the six months ending June 30, 2022. The company reported a loss of £1,300,653, a decrease from the £3,632,338 loss in 2021, with cash reserves of £5,799,495. Key advancements include the preparation to file an Investigational New Drug (IND) application for HEMO-CAR-T, bolstered scientific teams, and the establishment of a new facility in Manhattanville, New York. The company continues to explore the development of CDX antibodies and Chimeric Bait Receptor platforms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hemogenyx Pharmaceuticals will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York City from September 12-14, 2022. CEO Dr. Vladislav Sandler will discuss the company's progress in developing therapies for blood diseases. The conference will feature corporate presentations and investor meetings, accessible through a webcast. This event aims to boost Hemogenyx's visibility and establish its role in treating severe blood and autoimmune diseases, underlining the potential impact of their bone marrow transplantation technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Hemogenyx Pharmaceuticals announces the appointment of Stuart Tinch as Director of Quality, enhancing their commitment to Good Manufacturing Practice (GMP) standards. Tinch, with over seven years of experience, will focus on implementing quality systems for the company’s lead therapy, HEMO-CAR-T, currently being prepared for clinical trials. His previous role at Expression Therapeutics involved establishing GMP facilities, which aligns with Hemogenyx's goals of ensuring high-quality standards for its product candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management

FAQ

What is the current stock price of HEMOGENYX PHARMACEUTICALS (HOPHF)?

The current stock price of HEMOGENYX PHARMACEUTICALS (HOPHF) is $0.04 as of August 5, 2024.

What is the market cap of HEMOGENYX PHARMACEUTICALS (HOPHF)?

The market cap of HEMOGENYX PHARMACEUTICALS (HOPHF) is approximately 22.9M.

What is Hemogenyx Pharmaceuticals focused on?

The company is focused on developing new therapies and treatments for blood diseases.

What is the significance of the Chimeric Bait Receptor platform?

The platform shows promise in treating cancers like Non-Hodgkin Lymphoma and solid tumors.

How does Hemogenyx Pharmaceuticals expedite its R&D efforts?

The company utilizes Artificial Intelligence for protein structure simulations and in-house mRNA synthesis.

What recent FDA development has Hemogenyx Pharmaceuticals achieved?

The FDA has consented to Phase I trials of HEMO-CAR-T for AML, marking progress towards potentially life-saving treatments.

HEMOGENYX PHARMACEUTICALS

OTC:HOPHF

HOPHF Rankings

HOPHF Stock Data

22.93M
1.25B
10.27%
0.79%
Biotechnology
Healthcare
Link
United States of America
London